Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.37
ABT's Cash-to-Debt is ranked lower than
66% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. ABT: 0.37 )
Ranked among companies with meaningful Cash-to-Debt only.
ABT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.28 Max: N/A
Current: 0.37
Equity-to-Asset 0.44
ABT's Equity-to-Asset is ranked lower than
80% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ABT: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
ABT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.47 Max: 0.59
Current: 0.44
0.37
0.59
Interest Coverage 4.11
ABT's Interest Coverage is ranked lower than
81% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. ABT: 4.11 )
Ranked among companies with meaningful Interest Coverage only.
ABT' s Interest Coverage Range Over the Past 10 Years
Min: 4.25  Med: 10.89 Max: 17.59
Current: 4.11
4.25
17.59
Piotroski F-Score: 5
Altman Z-Score: 2.30
Beneish M-Score: -2.36
WACC vs ROIC
9.88%
10.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 11.03
ABT's Operating Margin % is ranked higher than
81% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. ABT: 11.03 )
Ranked among companies with meaningful Operating Margin % only.
ABT' s Operating Margin % Range Over the Past 10 Years
Min: 7.14  Med: 14.66 Max: 20.27
Current: 11.03
7.14
20.27
Net Margin % 6.74
ABT's Net Margin % is ranked higher than
68% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. ABT: 6.74 )
Ranked among companies with meaningful Net Margin % only.
ABT' s Net Margin % Range Over the Past 10 Years
Min: 6.71  Med: 15.23 Max: 31.3
Current: 6.74
6.71
31.3
ROE % 6.59
ABT's ROE % is ranked higher than
61% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. ABT: 6.59 )
Ranked among companies with meaningful ROE % only.
ABT' s ROE % Range Over the Past 10 Years
Min: 6.71  Med: 20.51 Max: 28.49
Current: 6.59
6.71
28.49
ROA % 3.10
ABT's ROA % is ranked higher than
63% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. ABT: 3.10 )
Ranked among companies with meaningful ROA % only.
ABT' s ROA % Range Over the Past 10 Years
Min: 2.98  Med: 8.77 Max: 12.12
Current: 3.1
2.98
12.12
ROC (Joel Greenblatt) % 30.38
ABT's ROC (Joel Greenblatt) % is ranked higher than
71% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. ABT: 30.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.81  Med: 33.56 Max: 65.75
Current: 30.38
0.81
65.75
3-Year Revenue Growth Rate 4.00
ABT's 3-Year Revenue Growth Rate is ranked lower than
51% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ABT: 4.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.9  Med: 9.7 Max: 15.2
Current: 4
-17.9
15.2
3-Year EBITDA Growth Rate -4.60
ABT's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. ABT: -4.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34  Med: 9.7 Max: 31.6
Current: -4.6
-34
31.6
3-Year EPS without NRI Growth Rate -17.40
ABT's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ABT: -17.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65.6  Med: 11.9 Max: 125.5
Current: -17.4
-65.6
125.5
GuruFocus has detected 4 Warning Signs with Abbott Laboratories $ABT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABT's 30-Y Financials

Financials (Next Earnings Date: 2017-07-20 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ABT Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 152,221 sh (New)
Stanley Druckenmiller 385,400 sh (New)
Paul Tudor Jones 26,300 sh (New)
Ray Dalio 104,100 sh (+813.16%)
Vanguard Health Care Fund 10,508,900 sh (+74.36%)
John Buckingham 133,574 sh (+53.38%)
Mairs and Power 406,484 sh (+27.27%)
Diamond Hill Capital 11,968,670 sh (+17.36%)
Jeremy Grantham 4,345,234 sh (+17.02%)
Richard Pzena 5,327,448 sh (+14.76%)
Murray Stahl 22,978 sh (+0.88%)
Jeff Auxier 78,672 sh (unchged)
Jeremy Grantham 173,800 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Robert Olstein Sold Out
Mario Gabelli 13,685 sh (-0.07%)
PRIMECAP Management 16,478,409 sh (-1.99%)
Pioneer Investments 978,987 sh (-18.53%)
Tom Russo 16,400 sh (-19.61%)
Ken Fisher 12,387 sh (-19.63%)
George Soros 329,181 sh (-21.47%)
Westport Asset Management 145,000 sh (-27.50%)
David Carlson 420,000 sh (-30.00%)
First Eagle Investment 2,974,455 sh (-60.38%)
Joel Greenblatt 130,054 sh (-84.91%)
Spiros Segalas 7,490,086 sh (-22.53%)
» More
Q3 2016

ABT Guru Trades in Q3 2016

Jim Simons 657,300 sh (New)
Steven Cohen 606,700 sh (New)
Stanley Druckenmiller 1,068,000 sh (+177.11%)
Mairs and Power 1,089,562 sh (+168.05%)
Jeremy Grantham 4,510,348 sh (+3.80%)
Ken Fisher 12,435 sh (+0.39%)
Mario Gabelli 13,695 sh (+0.07%)
Vanguard Health Care Fund 10,508,900 sh (unchged)
David Carlson 420,000 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
Tom Russo 16,400 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Joel Greenblatt Sold Out
Spiros Segalas Sold Out
Jeff Auxier 78,622 sh (-0.06%)
John Buckingham 133,239 sh (-0.25%)
Diamond Hill Capital 11,875,781 sh (-0.78%)
Murray Stahl 22,628 sh (-1.52%)
Manning & Napier Advisors, Inc 149,363 sh (-1.88%)
PRIMECAP Management 15,720,699 sh (-4.60%)
Richard Pzena 5,017,660 sh (-5.81%)
Pioneer Investments 908,362 sh (-7.21%)
George Soros 259,181 sh (-21.26%)
Paul Tudor Jones 16,600 sh (-36.88%)
Ray Dalio 62,000 sh (-40.44%)
First Eagle Investment 1,271,914 sh (-57.24%)
» More
Q4 2016

ABT Guru Trades in Q4 2016

Keeley Asset Management Corp 35,610 sh (New)
Joel Greenblatt 1,010,598 sh (New)
Jim Simons 2,980,400 sh (+353.43%)
Ray Dalio 80,200 sh (+29.35%)
Mairs and Power 1,333,036 sh (+22.35%)
Ken Fisher 14,794 sh (+18.97%)
Diamond Hill Capital 12,488,011 sh (+5.16%)
Manning & Napier Advisors, Inc 154,272 sh (+3.29%)
Vanguard Health Care Fund 10,758,900 sh (+2.38%)
Paul Tudor Jones 16,800 sh (+1.20%)
Richard Pzena 5,049,688 sh (+0.64%)
Jeff Auxier 78,664 sh (+0.05%)
David Carlson 420,000 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Tom Russo 16,400 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
First Eagle Investment Sold Out
Pioneer Investments Sold Out
Stanley Druckenmiller Sold Out
Steven Cohen Sold Out
John Buckingham 132,868 sh (-0.28%)
Murray Stahl 22,528 sh (-0.44%)
Mario Gabelli 13,625 sh (-0.51%)
Jeremy Grantham 4,484,944 sh (-0.56%)
PRIMECAP Management 14,859,619 sh (-5.48%)
George Soros 229,181 sh (-11.57%)
» More
Q1 2017

ABT Guru Trades in Q1 2017

Mairs and Power 4,270,907 sh (+220.39%)
Mario Gabelli 43,633 sh (+220.24%)
Vanguard Health Care Fund 17,608,199 sh (+63.66%)
Jeff Auxier 108,013 sh (+37.31%)
Manning & Napier Advisors, Inc 194,870 sh (+26.32%)
Ken Fisher 16,656 sh (+12.59%)
Jeremy Grantham 5,008,798 sh (+11.68%)
Murray Stahl 23,728 sh (+5.33%)
Jim Simons 3,124,266 sh (+4.83%)
John Buckingham 133,698 sh (+0.62%)
Tom Russo 16,400 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
David Carlson 420,000 sh (unchged)
Ray Dalio Sold Out
George Soros Sold Out
PRIMECAP Management 14,730,964 sh (-0.87%)
Diamond Hill Capital 12,291,387 sh (-1.57%)
Richard Pzena 2,922,096 sh (-42.13%)
Paul Tudor Jones 8,900 sh (-47.02%)
Joel Greenblatt 399,925 sh (-60.43%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NYSE:SYK, NYSE:BSX, NYSE:MDT, NAS:ISRG, NYSE:ZBH, NYSE:EW, OTCPK:SNNUF, NAS:ALGN, OTCPK:SONVY, NYSE:TFX, NYSE:VAR, OTCPK:CNVVY, OTCPK:WILLF, OTCPK:CHEOY, NAS:ABMD, NAS:MASI, OTCPK:GGNDF, OTCPK:FSPKF, OTCPK:EKTAY, NAS:NUVA » details
Traded in other countries:ABT.Argentina, ABTT34.Brazil, ABT.Chile, ABL.Germany, ABT.Mexico, ABT.Switzerland, 0Q15.UK,
Headquarter Location:USA
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Abbott manufactures and markets medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, coronary stents, catheters, infant formula, nutritional liquids for adults, vessel closure devices, and Lasik equipment. Abbott derives approximately 60% of sales outside the United States.

Guru Investment Theses on Abbott Laboratories

John Rogers Comments on Abbott Laboratories - Aug 18, 2016

In addition, cardiovascular muscle devices maker St. Jude Medical, Inc. (NYSE:STJ) popped +42.39% after a takeout offer. Specifically, Abbott Laboratories (NYSE:ABT) offered $ 46.75 in cash and 0.9 shares of Abbott stock for each share of St. Jude. The stock jumped more than 25% on the news of the offering.

From John Rogers (Trades, Portfolio)' second quarter 2016 market commentary.

Check out John Rogers latest stock trades

Mason Hawkins Comments on Abbott Laboratories - May 28, 2015

Abbott (ABT), a global healthcare company, reached our appraisal, resulting in a 120% return over our 4-year holding period. We are extremely appreciative of the value that CEO Miles White built for shareholders during our ownership.

From Mason Hawkins (Trades, Portfolio)’ Longleaf Partners Fund Q1 2015 Management Discussion.

Check out Mason Hawkins latest stock trades

Top Ranked Articles about Abbott Laboratories

Abbott Laboratories Releases 1st-Quarter Numbers The Medical Devices segment drove revenue
Abbott Laboratories (NYSE:ABT) released its first-quarter results April 19. Read more...
Abbott's St. Jude Medical Hit With FDA Warning Letter Letter was in response to company's failure to address issues concerning cardiac devices
In a warning letter dated April 12, the U.S. Food and Drug Administration criticized Abbott Laboratories (NYSE:ABT) for neglecting to properly investigate and resolve issues related to cybersecurity threats and a battery malfunction in its cardiac devices. Read more...
Abbott Sells More Mylan Holdings Abbott sold 44 million shares for a total consideration of $1.83 billion
Abbott (NYSE:ABT), the U.S. global health care company headquartered in Lake Bluff, Illinois, “confirmed that it sold 44 million shares of Mylan (NASDAQ:MYL) at $41.60 on March 23,” writes StreetInsider.com. Read more...
Alere Delays Filing for 2nd Year in a Row The company is investigating accounting errors
For the second year in a row, Alere Inc. (NYSE:ALR) has delayed filing its annual financial report with the Securities and Exchange Commission, citing possible accounting errors. Read more...
Abbott Laboratories Declares Quarterly Dividend Analysts' forecast increases for EPS and sales
Abbott Laboratories (NYSE:ABT) announced a regular quarterly dividend of 26.5 cents per share on Feb. 17. Read more...
Insider Buys Highlight for Week of Jan. 30 Insiders bought shares of General Electric and Abbott Laboratories
General Electric Co. (NYSE:GE): Senior Vice President Jeffrey S. Bornstein bought 5,000 shares Read more...
FDA Approves Abbott Labs' Devices for MRI Scans Patients with Assurity MRI pacemaker or Tendril MRI pacing lead can have full-body scans
Good news for heart patients implanted with Abbott Labs’ (NYSE:ABT) Assurity MRI pacemaker and Tendril MRI pacing lead. The U.S. Food and Drug Administration (FDA) has approved the two devices for total-body MRI scans. Read more...
Abbott Launches Neuropathic Pain Treatment System Company says system is superior to spinal cord stimulation
Abbott Laboratories (NYSE:ABT) announced through PR Newswire Jan. 18 that it has put on the market its Proclaim DRG Neurostimulation System, which has been created to stimulate the spinal ganglion in patients chronically affected by neuropathic pain. Read more...
Abbott Closes St. Jude Medical Deal Wednesday The purchase will add to company's EPS in 2017
Abbott Labs (NYSE:ABT) communicated through the PRNewswire on Dec. 30 that the closure of the purchase of St. Jude Medical (NYSE:STJ) for $25 billion is expected on Wednesday. Read more...
Abbott Labs to Buy St. Jude Medical for $25 Billion Company agreed on US FTC conditions for the closing of the deal
Abbott Labs (NYSE:ABT) agreed Dec. 27 to the conditions imposed by the U.S. Federal Trade Commission for the closing of the deal that will see Abbott purchase St. Jude Medical (NYSE:STJ) for a total consideration of $25 billion. Read more...

Ratios

vs
industry
vs
history
PE Ratio 45.61
ABT's PE Ratio is ranked lower than
69% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. ABT: 45.61 )
Ranked among companies with meaningful PE Ratio only.
ABT' s PE Ratio Range Over the Past 10 Years
Min: 5.78  Med: 11.15 Max: 49.12
Current: 45.61
5.78
49.12
Forward PE Ratio 17.61
ABT's Forward PE Ratio is ranked higher than
72% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. ABT: 17.61 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 49.19
ABT's PE Ratio without NRI is ranked lower than
78% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. ABT: 49.19 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.93  Med: 22.79 Max: 250.57
Current: 49.19
5.93
250.57
Price-to-Owner-Earnings 38.28
ABT's Price-to-Owner-Earnings is ranked lower than
100% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.96 vs. ABT: 38.28 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.53  Med: 12.25 Max: 2148.5
Current: 38.28
4.53
2148.5
PB Ratio 2.43
ABT's PB Ratio is ranked higher than
52% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. ABT: 2.43 )
Ranked among companies with meaningful PB Ratio only.
ABT' s PB Ratio Range Over the Past 10 Years
Min: 1.39  Med: 2.3 Max: 3.34
Current: 2.43
1.39
3.34
PS Ratio 3.03
ABT's PS Ratio is ranked higher than
53% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ABT: 3.03 )
Ranked among companies with meaningful PS Ratio only.
ABT' s PS Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.89 Max: 6.24
Current: 3.03
0.96
6.24
Price-to-Free-Cash-Flow 24.23
ABT's Price-to-Free-Cash-Flow is ranked lower than
52% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. ABT: 24.23 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.39  Med: 9.87 Max: 40.05
Current: 24.23
4.39
40.05
Price-to-Operating-Cash-Flow 17.11
ABT's Price-to-Operating-Cash-Flow is ranked higher than
54% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. ABT: 17.11 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.82  Med: 7.24 Max: 23.85
Current: 17.11
3.82
23.85
EV-to-EBIT 33.24
ABT's EV-to-EBIT is ranked higher than
86% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. ABT: 33.24 )
Ranked among companies with meaningful EV-to-EBIT only.
ABT' s EV-to-EBIT Range Over the Past 10 Years
Min: -214.2  Med: 16.5 Max: 5424.4
Current: 33.24
-214.2
5424.4
EV-to-EBITDA 20.16
ABT's EV-to-EBITDA is ranked higher than
92% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. ABT: 20.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 11.9 Max: 28.4
Current: 20.16
4.3
28.4
PEG Ratio 69.29
ABT's PEG Ratio is ranked lower than
95% of the 83 Companies
in the Global Medical Devices industry.

( Industry Median: 2.52 vs. ABT: 69.29 )
Ranked among companies with meaningful PEG Ratio only.
ABT' s PEG Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.25 Max: 140.36
Current: 69.29
0.44
140.36
Shiller PE Ratio 15.74
ABT's Shiller PE Ratio is ranked higher than
92% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 49.41 vs. ABT: 15.74 )
Ranked among companies with meaningful Shiller PE Ratio only.
ABT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9  Med: 12.76 Max: 17.98
Current: 15.74
9
17.98
Current Ratio 2.91
ABT's Current Ratio is ranked higher than
73% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. ABT: 2.91 )
Ranked among companies with meaningful Current Ratio only.
ABT' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.33 Max: 4.02
Current: 2.91
0.75
4.02
Quick Ratio 2.31
ABT's Quick Ratio is ranked higher than
78% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. ABT: 2.31 )
Ranked among companies with meaningful Quick Ratio only.
ABT' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.99 Max: 3.65
Current: 2.31
0.55
3.65
Days Inventory 107.65
ABT's Days Inventory is ranked higher than
62% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. ABT: 107.65 )
Ranked among companies with meaningful Days Inventory only.
ABT' s Days Inventory Range Over the Past 10 Years
Min: 80.31  Med: 103.72 Max: 145.14
Current: 107.65
80.31
145.14
Days Sales Outstanding 73.81
ABT's Days Sales Outstanding is ranked higher than
67% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. ABT: 73.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.85  Med: 71.85 Max: 145.87
Current: 73.81
56.85
145.87
Days Payable 54.45
ABT's Days Payable is ranked lower than
58% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. ABT: 54.45 )
Ranked among companies with meaningful Days Payable only.
ABT' s Days Payable Range Over the Past 10 Years
Min: 35.38  Med: 41.44 Max: 73.71
Current: 54.45
35.38
73.71

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.39
ABT's Dividend Yield % is ranked higher than
76% of the 191 Companies
in the Global Medical Devices industry.

( Industry Median: 1.33 vs. ABT: 2.39 )
Ranked among companies with meaningful Dividend Yield % only.
ABT' s Dividend Yield % Range Over the Past 10 Years
Min: 1.41  Med: 4.88 Max: 7.9
Current: 2.39
1.41
7.9
Dividend Payout Ratio 1.17
ABT's Dividend Payout Ratio is ranked lower than
78% of the 122 Companies
in the Global Medical Devices industry.

( Industry Median: 0.40 vs. ABT: 1.17 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ABT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.42  Med: 0.57 Max: 13.4
Current: 1.17
0.42
13.4
3-Year Dividend Growth Rate 22.90
ABT's 3-Year Dividend Growth Rate is ranked higher than
81% of the 81 Companies
in the Global Medical Devices industry.

( Industry Median: 8.00 vs. ABT: 22.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ABT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -31.2  Med: 11.5 Max: 22.9
Current: 22.9
-31.2
22.9
Forward Dividend Yield % 2.46
ABT's Forward Dividend Yield % is ranked higher than
76% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. ABT: 2.46 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.24
ABT's 5-Year Yield-on-Cost % is ranked lower than
66% of the 219 Companies
in the Global Medical Devices industry.

( Industry Median: 1.97 vs. ABT: 1.24 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ABT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.72  Med: 2.49 Max: 4.03
Current: 1.24
0.72
4.03
3-Year Average Share Buyback Ratio 1.60
ABT's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ABT: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: 0.5 Max: 2.2
Current: 1.6
-0.8
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.25
ABT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
84% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. ABT: 1.25 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.36  Med: 0.86 Max: 1.81
Current: 1.25
0.36
1.81
Price-to-Intrinsic-Value-DCF (Earnings Based) 4.60
ABT's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
92% of the 25 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. ABT: 4.60 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.60
ABT's Price-to-Median-PS-Value is ranked lower than
83% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. ABT: 1.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.51  Med: 0.87 Max: 3.16
Current: 1.6
0.51
3.16
Price-to-Peter-Lynch-Fair-Value 4.25
ABT's Price-to-Peter-Lynch-Fair-Value is ranked lower than
91% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 1.61 vs. ABT: 4.25 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.01 Max: 6.45
Current: 4.25
0.33
6.45
Earnings Yield (Greenblatt) % 3.00
ABT's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. ABT: 3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 5.7 Max: 18.5
Current: 3
0.1
18.5
Forward Rate of Return (Yacktman) % 16.27
ABT's Forward Rate of Return (Yacktman) % is ranked higher than
62% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.85 vs. ABT: 16.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -18.6  Med: 13.2 Max: 31.8
Current: 16.27
-18.6
31.8

More Statistics

Revenue (TTM) (Mil) $22,303
EPS (TTM) $ 0.96
Beta1.54
Short Percentage of Float0.88%
52-Week Range $36.76 - 45.84
Shares Outstanding (Mil)1,728.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 26,321 27,487 29,239
EPS ($) 2.45 2.71 3.06
EPS without NRI ($) 2.45 2.71 3.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.26%
Dividends per Share ($) 1.10 1.16 1.24
» More Articles for ABT

Headlines

Articles On GuruFocus.com
Abbott Announces CE Mark for TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ May 09 2017 
Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac May 08 2017 
Abbott Announces National Reimbursement for FreeStyle® Libre in France, Providing Access to Revolut May 08 2017 
AbbVie Reports Humira Sales Growth in 1st Quarter Apr 28 2017 
AbbVie’s Humira Revenue Up 15% Despite Patent Cliff Fears Apr 28 2017 
Abbott Introduces Science-Based Nutrition Drinks to Help Patients Have a Better Recovery from Surger Apr 26 2017 
Abbott Laboratories Releases 1st-Quarter Numbers Apr 20 2017 
The Better Big Pharma Stock: AbbVie or Gilead? Apr 18 2017 
Abbott and Alere Amend Terms of Merger Agreement Apr 14 2017 
Abbott's St. Jude Medical Hit With FDA Warning Letter Apr 13 2017 

More From Other Websites
Abbott Labs (ABT) Down 2.3% Since Earnings Report: Can It Rebound? May 22 2017
Give Your Grad The Gift Of A Million-Dollar Dividend Stock Portfolio For A Few Hundred Bucks May 19 2017
The Zacks Analyst Blog Highlights: General Dynamics, EOG Resources, Abbott, Northrop Grumman and... May 17 2017
Abbott Lab Well Poised on Strong EPD, St. Jude Integration May 17 2017
Analyst Reports for Abbott, EOG, General Dynamics & Others May 16 2017
Goldman Starts Abbott Laboratories at 'Neutral' May 16 2017
Retired baseball player DeCinces found guilty of insider trading May 12 2017
Abbott Announces CE Mark for TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ May 09 2017
Cramer: These Sectors Look Bullish (Part III) May 09 2017
Abbott Laboratories – Value Analysis (NYSE:ABT) : May 8, 2017 May 08 2017
Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac... May 08 2017
Abbott Announces National Reimbursement for FreeStyle® Libre in France, Providing Access to... May 08 2017
Abbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : May 5, 2017 May 05 2017
S&P Dividend Aristocrats: Which Stocks Make the List? May 05 2017
Alere, set to be acquired by Abbott, dealt setback in Medicare case May 01 2017
Global med-tech firms, India locked in tussle after stent price sting Apr 28 2017
Abbott Introduces Science-Based Nutrition Drinks to Help Patients Have a Better Recovery from... Apr 26 2017
Global Market For Medical Implants To Hit Nearly $27 Billion In 5 Years Apr 25 2017
Cramer's lightning round: Nobody ever made money betting against this CEO Apr 24 2017
AB's 4-star stock picks Apr 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat